HEOR and Epidemiology Research from Analysis Group Featured at AMCP Nexus Meeting

October 23, 2023

Research from Analysis Group’s HEOR, Epidemiology & Market Access practice was featured with 10 posters at the Academy of Managed Care Pharmacy’s (AMCP’s) annual Nexus Meeting, which was held October 16–19, 2023, in Orlando, FL. Four of the abstracts received ribbon honors, including:

Gold ribbon

  • “Time-to-next treatment and overall survival among White and Black patients with homologous recombination repair positive metastatic castration-resistant prostate cancer who initiated first-line therapy,”coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, Associate Laura Morrison, Senior Research Professional Annalise Hilts, and Research Professional Lilian Diaz – in collaboration with researchers from the Winship Cancer Institute at Emory University, the Duke Cancer Center, and Janssen Scientific Affairs.

Silver ribbon

  • “Real-world economic burden associated with progression from metastatic castration-sensitive to metastatic castration-resistant prostate cancer,”coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Associate Laura Morrison, and Senior Research Professionals Ana Urosevic and Frederic Kinkead – in collaboration with researchers from the Duke Cancer Center and Janssen Scientific Affairs.
  • “Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder,”coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice Presidents Martin Cloutier and Marjolaine Gauthier-Loiselle, Associate Rebecca Bungay, Senior Research Professional Deborah Chan, and Data Scientist Kathleen Chen – in collaboration with researchers from Otsuka Pharmaceutical Development & Commercialization.

Bronze ribbon

  • “Long-term temporal trends of healthcare cost associated with nivolumab plus ipilimumab (N+I) and pembrolizumab plus axitinib (P+A) as first-line (1L) treatment in advanced or metastatic renal cell carcinoma (aRCC) in real-world setting,”coauthored by an Analysis Group team – including Managing Principal Eric Wu, Vice President Keith Betts, and Manager Ella Du – in collaboration with researchers from Bristol Myers Squibb.

Additional poster presentations included:

  • “Impact of social determinants of health on esketamine initiation among patients with treatment-resistant depression in the United States,”coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Masha Zhdanava, and Associates Aditi Shah and Arthur Voegel – in collaboration with researchers from Depression MD, the Yale School of Medicine, and Janssen Scientific Affairs.
  • “Impact of next-generation sequencing versus polymerase chain reaction testing on costs and clinical outcomes throughout the treatment journey of patients with metastatic non-small cell lung cancer,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice Presidents Bruno Émond and Marie-Hélène Lafeuille, Associates Laura Morrison and Deo Mujwara, and Senior Research Professional Annalise Hilts – in collaboration with researchers from The University of Chicago Pritzker School of Medicine and Janssen Scientific Affairs.
  • “Non-medical switching or discontinuation patterns among patients with non-valvular atrial fibrillation treated with direct oral anticoagulants in the United States,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Hela Romdhani, Senior Research Professional Gabrielle Caron-Lapointe, and Research Professional Anabelle Tardif-Samson – in collaboration with researchers from Janssen Scientific Affairs.
  • “Burden of moderate-to-severe acne vulgaris among commercially insured patients in the US: A claims-based analysis,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick Gagnon, and Manager Elizabeth Serra – in collaboration with researchers from The Dermatology and Skin Care Center of Birmingham, Bausch Health, and Ortho Dermatologics.
  • “Assessment of access barriers to rifaximin among patients with overt hepatic encephalopathy using adjudicated claims data,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick Gagnon, Associate Jessica Maitland, and Research Professional Kana Yokoji – in collaboration with researchers from Weill Cornell Medicine, Bausch Health, and Salix Pharmaceuticals.
  • “Real-world treatment patterns and characteristics of Medicare patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin-ejfv,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Manager Qing Liu, and Associates Alexandra Greatsinger and Angela Lax – in collaboration with researchers from the Dana-Farber Cancer Institute, Astellas Pharma, and Seagen.

Read more about AMCP Nexus 2023